Clinical trials: Intrauterine Growth Retardation (IUGR)
Fetal Growth Retardation, Stillbirth
Prediction of Late Fetal Growth Restriction Using Cerebroplacental Ratio
To investigate the screening performance of CPR and biophysical profile score for the prediction of composite of adverse neonatal morbidity and mortality and operative delivery (CS or instrumental) for intrapartum fetal distress…
- Conditions
- Fetal Growth Retardation, Stillbirth, Neonatal Respiratory Failure, Neonatal Death
- Trial name
- NCT04640467
- Testing
- Biophsical profile, Cerebroplacental ratio
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Assiut University
Intrauterine Growth Restriction
Intra Uterine Growth Restriction
Intrauterine growth restriction (IUGR) is associated with an increase in perinatal mortality and morbidity, as well as longer-term neurological, cognitive, cardiovascular and endocrine complications.
- Trial name
- IUGR (NCT03866863)
- Testing
- Intrauterine growth restriction (IUGR)
- Where
- France
- Volunteers
- 31,052 people
- Sponsor
- Hospices Civils de Lyon
Stillbirth
Revealed Versus Concealed Cerebroplacental Ratio
The purpose of this study is to evaluate the role of an integrated strategy at selecting fetuses for delivery at term based on a combination of fetal biometry and cerebroplacental ratio (CPR) to reduce stillbirth rate and adverse…
- Trial name
- NCT02907242
- Testing
- Revealment
- Where
- 9 sites in Chile, Czechia and 4 more
- Volunteers
- 11,582 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development
Maternal Adversity, Vulnerability and Neurodevelopment
Maternal Adversity Vulnerability and Neurodevelopment (MAVAN) project is a prospective community-based, pregnancy and birth cohort of Canadian mother-child dyads.
- Conditions
- Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development, Infant Behavior
- Trial name
- MAVAN (NCT03434457)
- Where
- Canada
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Growth Hormone Deficiency, Small-for-gestational Age
Growth and Asymmetric diMethylArginine
Principal objective : Validation of a handy biochemical parameter, plasma concentration of Asymmetric DimethylArginine (ADMA), based on a recognize biochemical parameter, the dilation of the brachial artery, at ultrasound…
- Trial name
- GAMMA (NCT03422081)
- Testing
- arterial doppler ultrasound
- Where
- 2 sites in France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Lille
Fetal Growth Retardation
Day to Day Variation in Fetal Heart Rate Variability
This study evaluates the day-to-day variation in fetal heart rate variability based on non-invasive fetal-ECG (NI-FECG). Furthermore, the effect of fetal movements on fetal heart rate variability will be assessed.
- Trial name
- (FHRV) (NCT04289350)
- Testing
- fetal heart rate variability
- Where
- Denmark
- Volunteers
- 44 people
- Sponsor
- University of Aarhus
Late-onset Fetal Growth Restriction
qCTG and Doppler Ultrasound in the Detection of Hypoxia Among FGR Fetuses
To evaluate the benefits of combining Doppler measurements of placental/fetal blood vessels with computerized cardiotocography (quantitative cardiotocogrpahy - qCTG) in the detection of fetal hypoxia (pH < 7.20) among late-onset…
- Trial name
- NCT04447248
- Testing
- QDSP Protocol
- Volunteers
- 1,714 people
- Sponsor
- Orthogyn Medical Center, Bulgaria
Intrauterine Growth Restriction
IUGR; Cause and Relationship
Intrauterine growth restriction (IUGR) is a pregnancy complication in about 3-5% of all pregnancies in Sweden. IUGR fetuses are at high risk of morbidity and death.
- Trial name
- NCT05142644
- Testing
- ultrasound
- Where
- Sweden
- Volunteers
- 80,000 people
- Sponsor
- Karolinska Institutet
Preeclampsia and Intrauterine Growth Restriction
Placental Insufficiency Microcirculation Quantification by Ultrafast Doppler (MICRODOPPLER PLACENTA)
To identify fetuses small for their gestational-age who have reached their appropriate growth potential from growth-restricted fetuses due to placental insufficiency is uneasy.
- Trial name
- NCT03860103
- Where
- France
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Fetal Growth Restriction, Antiphospholipid Syndrome
Antiphospholipid Antibodies and Fetal Growth Restriction
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and…
- Trial name
- NCT01538134
- Where
- Panama
- Volunteers
- 90 people
- Sponsor
- Saint Thomas Hospital, Panama
Sleep, Pregnancy
Halifax PrenaBelt Trial
Back and right-sided sleeping position in pregnant women has recently emerged as a potential risk factor for low birthweight (LBW) and stillbirth (SB) in the medical literature.
- Conditions
- Sleep, Pregnancy, Stillbirth, Infant, Low Birth Weight
- Trial name
- NCT02377817
- Testing
- PrenaBelt
- Where
- Canada
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Allan Kember
Preeclampsia
Agouti-related Peptide (AgRP) in Healthy Mothers and Mothers With Preeclampsia and Their Offspring
The study is focused on the investigation of possible associations between plasma/serum levels of agouti related peptide (AgRP) and its genetic background in healthy women with physiological pregnancy (non-preeclamptic) and women…
- Trial name
- NCT01042210
- Where
- Czechia
- Volunteers
- 84 people
- Sponsor
- Masaryk University
Pregnancy, Primiparity
MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study
The purpose of this study is to determine whether close monitoring of patients with a high sFlt1 plasma level between 25 and 28 weeks of gestation (i.e.
- Conditions
- Pregnancy, Primiparity, Hypertension, Preeclampsia
- Trial name
- MOMA (NCT00763672)
- Testing
- Transmission of sFlt-1 results to the investigator, No transmission of the sFlt-1 results to the investigator
- Where
- France
- Volunteers
- 1,040 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Fetal Growth Restriction, Gut Microbiota
Gut Microbiota, SCFAs and Glucolipid Metabolism in Pregnant Women With Abnormal Fetal Size and Their Newborns
Abnormal fetal size includes fetal growth restriction and fetal macrosomia. Onset is closely related to maternal nutrition metabolism.
- Conditions
- Fetal Growth Restriction, Gut Microbiota, Fetal Macrosomia, Glucolipid Metabolism
- Trial name
- NCT04399434
- Testing
- test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Healthy Volunteers
Early Environmental and Maternal Determinants of Airway Inflammation in Wheezing Disorders in Infants
This study collects data on microbiological, genetic and environmental factors, as well as lung function parameters (e.g. spirometry, body plethysmography, lung-MRI) to assess the complex interaction of predisposing risk factors…
- Trial name
- NCT04286464
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Multiple Micronutrient Deficiencies During Pregnancy
Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso
Intrauterine Growth Retardation is the most important determinant of mortality and morbidity in the neonatal period. It is also a very important factor in predicting nutritional status, health and development in childhood.
- Trial name
- NCT00642408
- Testing
- Multiple micronutrient supplements (MMN), IFA
- Where
- Burkina Faso
- Volunteers
- 1,370 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Intrauterine Growth Restriction
Impact of Antioxidant Juice Intake on Brain Injury and Placental Pathology in Infants With Intrauterine Growth Restriction (IUGR)
Infants diagnosed with intrauterine growth restriction are at increased risk for brain injury in the neonatal period, and eventually increased risk for adverse long-term neurodevelopmental outcomes.
- Trial name
- NCT04394910
- Testing
- Pomegranate Juice
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Brigham and Women's Hospital
Preeclampsia
LMWH to Prevent Preeclampsia and Fetal Growth Restriction
The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history…
- Trial name
- NCT00260520
- Testing
- Dalteparin
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Florence
Fetal Growth Retardation
MAXOMAT ® in the Treatment of Severe Early Onset Intrauterine Growth Retardation on Pre-pubertal Children
1. To test for equivalence in terms of catch-up growth between the 2 therapeutic regimens 2. To specify the best period of treatment 3. To assess the efficacy of treatment based on final adult height of these children
- Trial name
- NCT00452491
- Testing
- somatropin
- Where
- France
- Volunteers
- 306 people
- Sponsor
- Sanofi
s100b, Hypoxia-Ischemia, Brain
Cord Blood S100B Protein Concentration in Neonates With Fetal Growth Restriction
S100B protein is a biomarker that increases following central nervous system (CNS) damage. Measuring this protein's levels may allow for the early identification of infants at high risk for developmental abnormalities, such as…
- Conditions
- s100b, Hypoxia-Ischemia, Brain, Fetal Growth Restriction (FGR)
- Trial name
- NCT06893926
- Testing
- Prenatal ultrasound examination with blood flow analysis, Umbilical cord blood gas analysis, Umbilical cord blood S100B protein level
- Where
- Poland
- Volunteers
- 120 people
- Sponsor
- Institute of Mother and Child, Warsaw, Poland